Physicians' Academy for Cardiovascular Education

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Paris/London

Video navigation menu

  • Trial design and primary results of ODYSSEY OUTCOMES 0:31
  • The effect of alirocumab in subgroups: patients with diabetes and those with polyvascular disease 6:29
  • Effect of alirocumab in patients with prior CABG 9:10
  • What kind of myocardial infarction did alirocumab prevent? 10:34
  • Effects of alirocumab on Lp(a) and depending on Lp(a) level at baseline 11:07

Educational information

This lecture by prof. Ph. Gabriel Steg was part of an accredited symposium "PCSK9i, changing practice in cardiology: The emerging story" held during ESC 2019 in Paris, France.

Faculty

Ph. Gabriel Steg is a cardiologist in the Hôpital Bichat, Paris, France. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Amgen, Sanofi-Regeneron, The Medicines Company and Draupnir Bio.

View slides of this presentation

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: